Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

George Yancopoulos, co-founder of biotech firm Regeneron, has purchased almost all of the condominium units in a mixed-use ...

Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug ...

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: Regeneron Pharmaceuticals ( REGN 0.40%) and Moderna ( MRNA -0.79%).

Baird lowered the firm’s price target on Regeneron (REGN) to $652 from $759 and keeps a Neutral rating on the shares. The firm said its Eylea ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

Truist lowered the firm’s price target on Regeneron (REGN) to $975 from $1,004 and keeps a Buy rating on the shares. The firm notes Regeneron ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion ...